Diltiazem potentiates the cytotoxicity of gemcitabine and 5-fluorouracil in PANC-1 human pancreatic cancer cells through inhibition of P-glycoprotein

• Published in: Life sciences (1973) Vol. 262; pp. 118518 - 12
• Main Authors: El-Mahdy, Hesham A., El-Husseiny, Ahmed A., Kandil, Yasser I., Gamal El-Din, Ayman M.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01.12.2020; Elsevier BV
• Subjects: 5-Fluorouracil; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Apoptosis; Apoptosis - drug effects; ATP Binding Cassette Transporter, Subfamily B - antagonists & inhibitors; Biomarkers; Calcium; Calcium channel blockers; Calcium Channel Blockers - administration & dosage; Calcium Channel Blockers - pharmacology; Cancer; Caspase-3; CD44 antigen; Cell cycle; Cell Cycle Checkpoints - drug effects; Cell Line, Tumor; Cell Survival - drug effects; Cell viability; Cytotoxicity; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Deoxycytidine - pharmacology; Diltiazem; Diltiazem - administration & dosage; Diltiazem - pharmacology; DNA fragmentation; Drug Synergism; Flow cytometry; Fluorouracil - administration & dosage; Fluorouracil - pharmacology; Gemcitabine; Glycoproteins; Humans; Immunoblotting; P-Glycoprotein; PANC-1; Pancreatic cancer; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - pathology; Pheochromocytoma cells; Stem cells; Toxicity; Tumors; P-glycoprotein; Gemcitabine; 5-Fluorouracil; Diltiazem; Pancreatic cancer; PANC-1
• ISSN: 0024-3205; 1879-0631
• DOI: 10.1016/j.lfs.2020.118518

Pancreatic cancer (PC) is one of the most aggressive tumors with dismal survival and a high death rate due to chemotherapeutic failure. P-glycoprotein (P-gp) plays a pivotal role in PC response to gemcitabine and 5-fluorouracil (5-FU). Diltiazem, a calcium channel blocker, is a P-gp inhibitor. In the current study, we investigated the hypothesis that targeting of P-gp by diltiazem can enhance the cytotoxicity of gemcitabine and 5-FU against human pancreatic cancer cells. The cytotoxic effect of diltiazem, gemcitabine, and 5-FU in single and combined forms against PANC-1 and AsPC-1 cells were assayed by MTT. Flow cytometric analysis was used for the determination of cell cycle, apoptosis, and stemness markers in PC cells. Besides, immunoblotting was used for assessment of Bax, caspase 3, cyclin D1, and P-gp expressions. Diltiazem co-treatment, either with gemcitabine or 5-FU, synergistically reduced cell viability, induced apoptosis, and caused cell cycle arrest. In addition, diltiazem co-treatment decreased the expressions of stem cell markers CD24 and CD44, increased the expressions of Bax and cleaved caspase 3, enhanced DNA fragmentation, and attenuated cyclin D1 and P-gp expressions as compared to cells treated with either gemcitabine or 5-FU alone. Our findings suggest that diltiazem may be potential neoadjuvant therapy to enhance the response of PC to gemcitabine or 5-FU treatment. •P-glycoprotein (P-gp) pump reduces the intracellular accumulation of chemotherapy.•Combined diltiazem with gemcitabine or 5-FU significantly decreases P-gp expression.•Pancreatic cancer stem cells are significantly reduced by diltiazem co-treatment.•Diltiazem enhances the cytotoxicity of gemcitabine and 5-FU against PANC-1 cells.